Quest Diagnostics  

3 Giralda Farms
Madison,  NJ  07940

United States
http://www.questforhealthsystems.com
  • Booth: 5313

Profile

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. We serve half of the physicians and hospitals in the United States. QuestDiagnostics.com.


 Videos

Quest Diagnostics: 50 years In Healthcare

 Press Releases

  •  Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.

    Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/ 

    At a ceremony at the company's flagship clinical laboratory in Teterboro, NJ, the company's chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest's predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.

    "Fifty years ago this month, Paul Brown began our company with the simple idea of finding a better way to deliver diagnostic insights that can empower better health. From this concept, Quest Diagnostics has evolved to be the leading provider of diagnostic information services, whose expertise, innovations, scale and speed have been at the center of the U.S. healthcare system for the past half-century," said Mr. Rusckowski. "Our 43,000 employees are dedicated to meeting the coming challenges in healthcare and making this a healthier world."

    Quest Diagnostics was founded in April 1967 as Metropolitan Pathology Laboratory, Inc. (MetPath) in a two-bedroom apartment in Manhattan to provide better lab testing to area hospitals. Corning Glass Works acquired the company in 1982, grew the business through hundreds of acquisitions and later spun it off as a publicly traded company under the name Quest Diagnostics, at the beginning of 1997.

    Over the span of 50 years, Quest has developed countless innovative diagnostic information services, with several firsts for clinical laboratory tests in areas such as women's health, genetics, infectious diseases and cancer. Last year, the company was the first commercial laboratory to receive U.S. Food and Drug Administration emergency use authorization for a molecular Zika test.

    Today, Quest provides thousands of laboratory services, from genetic tests to predict cancer risk to biological tests for diabetes and heart disease, to empower people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, the company's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. One in three American adults and one in two physicians and hospitals use the company's services each year.

    Quest is recognized as a leading company by organizations and publications, such as Fortune, Barron's, the Dow Jones Sustainability Index and others. The company is the only diagnostic information services provider ranked among Forbes Most Admired Companies. Quest had $7.5 billion in revenues in 2016.

    To learn more about Quest's 50th anniversary visit www.QuestDiagnostics.com/50Years.

    About the Quest Diagnostics Health In Your Hand Anniversary Grant Program

    The Quest Diagnostics Charitable Foundation selected two of the recipients of the Health In Your Hands Grants. One of the winners, Autism Speaks, was selected by employee vote. The candidates were selected based on mission to improve health, national or global scale, and intended use of the grants to improve health or healthcare.

    • The American Red Cross will use its Health In Your Hands Grant to support its blood donation and disaster relief programs.
    • The National Ovarian Cancer Coalition will use the grant for its Faces of Hope program, which includes its TEAL Totes program to distribute resources to woman at diagnosis and NOCC CancerConnect online community for patients and caregivers to connect to share their stories and provide peer to peer support.
    • Autism Speaks will use the grant to support researchers to explore the genetic underpinnings of autism and advancing toward better interventions.

    About Quest Diagnostics

    Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

    Quest, Quest Diagnostics, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks are the property of their respective owners.

    About the American Red Cross

    The American Red Cross shelters, feeds and provides emotional support to victims of disasters; supplies about 40 percent of the nation's blood; teaches skills that save lives; provides international humanitarian aid; and supports military members and their families. The Red Cross is a not-for-profit organization that depends on volunteers and the generosity of the American public to perform its mission. For more information, please visit redcross.org or cruzrojaamericana.org, or visit us on Twitter at @RedCross.

    About the National Ovarian Cancer Coalition

    For more than 25 years, the National Ovarian Cancer Coalition has been committed to raising awareness, promoting education, and funding research in support of women, families, and communities touched by ovarian cancer. The NOCC is well established as an important national advocate for patients and families struggling with ovarian cancer, and remains steadfast in its mission to save lives by fighting tirelessly to prevent and cure ovarian cancer, and to improve the quality of life for survivors. For more information or to find a chapter near you, please visit http://www.ovarian.org, follow us @noccnational and join the conversation with #NOCC and #KnowOvarian.

    About Autism Speaks

    Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the life span, for the needs of individuals with autism and their families. We do this through advocacy and support; increasing understanding and acceptance of autism spectrum disorder; and advancing research into causes and better interventions for autism spectrum disorder and related conditions. We empower people with autism and their families with resources, online tools and information covering the life span. To find resources, join a fundraising walk or make a donation, go to www.AutismSpeaks.org.

    For Media:

    "When I founded MetPath in a New York apartment, it was my goal to ensure patients could have quality diagnostic services to ensure the best health outcomes possible," said Paul A. Brown, M.D., founder of MetPath, the predecessor business of Quest Diagnostics. "Today, Quest continues that legacy by providing laboratory services to one in three adult Americans and half the physicians and hospitals in the United States through its first-in class diagnostic services. It is marvelous to see the Quest organization evolve over the years to have such a tremendous positive impact on the world."

    "There is inherent social value in the work we do each day to empower better health outcomes," said Jeffrey S. Shuman, senior vice president and chief human resources officer, Quest Diagnostics. "We are excited to be able to engage all of our colleagues at Quest to mark our 50th anniversary in a positive and impactful way. By partnering with our employees and non-profit organizations with aligned interests, we can build meaningful value for our patients, our customers and the communities in which we work and live."

    "We are honored to be a Health In Your Hands Grant recipient and are grateful to Quest Diagnostics Charitable Foundation for their generous support of the lifesaving work of the American Red Cross in New Jersey, across the country and around the world," said Ana Montero, CEO, American Red Cross New Jersey Region. "We salute Quest Diagnostics on their 50th anniversary and are especially thankful to be a part of this milestone event."

    "On behalf of the women and families affected by ovarian cancer, it is with deep gratitude that we accept this generous donation from Quest Diagnostics," states David Barley, CEO of the National Ovarian Cancer Coalition. "Ovarian Cancer is the 5th leading cause of cancer-related death in women. These critical funds will help support the NOCC's local and national programs for earlier awareness, quality of life for survivors, and important research. Congratulations to Quest Diagnostics for 50 years of service to the healthcare community."

    "We deeply appreciate the Health In Your Hands Grant, which will help fuel our mission to promote solutions across the spectrum and throughout the life span," said Mathew Pletcher, co-director of the Autism Speaks MSSNG genetic research program. "We applaud Quest Diagnostics on its 50th anniversary for its vision and for investing in the future of autism research."

    Contacts:
    Wendy Bost, Quest Diagnostics (Media): 973-520-2800
    Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

  • MADISON, N.J., Feb. 16, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2017 by Fortune. 

    The annual survey designated Quest Diagnostics as one of only six companies in the "Health Care: Pharmacy and Other Services" industry to attain Most Admired status, and the only diagnostic information services company to attain the designation. This is the second consecutive year Quest has attained the Most Admired designation.    

    "We are honored to be included once again among this prestigious group of companies attaining this distinction," said Steve Rusckowski, Chairman, President and CEO. "Our 43,000 dedicated employees are leading the way in delivering the diagnostic insights which empower people to take action to improve health outcomes." 

    Fortune's "World's Most Admired Companies" list is based on surveys of 680 companies from 28 countries asking executives, directors and analysts to rate companies within their own industry on nine reputation drivers considered to be crucial to a company's global success. These drivers include financial soundness, long-term investment value, people management, social responsibility, use of assets, quality of management, quality of products/services, innovation and global competitiveness. 

    About Quest Diagnostics

    Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

    Quest Diagnostics Contacts: Shawn Bevec (Investors): 973-520-2900 Denny Moynihan (Media): 973-520-2800

    SOURCE Quest Diagnostics

  • MADISON, N.J., Feb. 16, 2017 /PRNewswire/ -- Harvard Pilgrim Health Care now offers physicians Data Diagnostics®, a point-of-care health analytics technology from Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) that is designed to help close costly gaps in care and improve health outcomes.

    Accessible through a physician's existing electronic health record (EHR), Data Diagnostics produces patient-specific reports, often in seconds, that help inform clinical decisions, diagnostic coding and other actions that affect quality of care and reimbursement. Physicians can order these reports in real time through their EHR for eligible Harvard Pilgrim patients in Connecticut, Massachusetts, New Hampshire and Maine. No new technology, and minimal training, is required to order reports for patients.

    Harvard Pilgrim is committed to providing tools that support physician's access to relevant data within the physicians current workflow. Data Diagnostics gives physicians the ability to order and access reports in real time in their existing workflow. The reports employ the EHR's existing data on the patient as well as patient-specific information from Quest's 20 billion lab test results and Inovalon's 139 million unique patients within their MORE2 Registry clinical datasets.

    "One of Harvard Pilgrim's goals is to empower our physicians to succeed under value-based care and innovative risk-sharing models," said Gaurish Chandrashekhar, director of revenue management, Harvard Pilgrim. "We believe Data Diagnostics may help enable this transition by supporting accurate clinical documentation, which is vital to risk accuracy and appropriate reimbursement, as well as improved quality. We expect this tool will strengthen our relationships with physicians while simultaneously improving provider-patient interactions, which is a win-win scenario."

    Proper coding of a patient's care supports high quality care as well as reimbursement under value-based care models that tie compensation to quality and outcomes rather than individual medical services.

    "The shift from volume to value is all about providing better care," said David Freeman, general manager, information ventures, Quest Diagnostics. "Harvard Pilgrim has a track record of innovation in health care, and recognizes that good care and cost efficiency often go hand in hand. We look forward to providing Data Diagnostics and its actionable insights to Harvard Pilgrim-serving physicians to aid the delivery of quality care for patients."

    About Data Diagnostics
    Data Diagnostics, a joint solution offered by Quest Diagnostics and Inovalon, is a point-of-care health analytics technology that produces patient-specific reports in real time to help physicians easily identify and address gaps in quality, risk, utilization and medical history. Reports draw from information in the physician's EHR as well as data from Quest's 20 billion clinical laboratory test results and Inovalon's clinical datasets on more than 139 million Americans. Physicians can order Data Diagnostics reports in their existing workflow and EHR, receiving an easy to read actionable report often within seconds. Data Diagnostics has won several industry awards, including the Best in Biz Most Innovative Product of the Year for Healthcare Award. Data Diagnostics is part of the Quest Diagnostics Quanum™ suite of healthcare information and technology solutions. www.QuestDiagnostics.com/DataDiagnostics

    About Harvard Pilgrim Health Care
    Harvard Pilgrim is a not-for-profit health services company that, along with its subsidiaries, is improving the well-being of its 2.7 million customers. Harvard Pilgrim's flagship health plans in New England provide health coverage to 1.3 million members, while another 1.4 million individuals are served through Health Plans, Inc., a subsidiary that provides integrated care management, health coaching and plan administration solutions to self-funded employers nationwide. Founded in 1969, Harvard Pilgrim has built its reputation on innovation and collaboration with a goal of lowering health care costs, improving care and enhancing the overall member experience. It is known for its excellent clinical programs, customer service, health improvement strategies and innovative tools that offer consumers greater transparency and empower them to make better decisions about their health care. Harvard Pilgrim is home to the Harvard Pilgrim Health Care Institute, a unique collaboration with Harvard Medical School. As Harvard Medical School's Department of Population Medicine, the Institute is the only appointing department of a U.S. medical school housed within a health plan. Funded primarily through external government and private sources, it provides critical information to all levels of our health care system on issues affecting population health and health care delivery. Harvard Pilgrim is consistently among America's highest-rated health plans according to an annual ranking of the nation's best health plans by the National Committee for Quality Assurance (NCQA)*.

    *Harvard Pilgrim Health Care (private HMO/POS and PPO plans) and Harvard Pilgrim Health Care of New England (private HMO/POS plans) have been rated 4.5 out of 5 in NCQA's Private Health Insurance Plan Ratings 2016-17. NCQA's Private Health Insurance Plan Ratings 2015-16. NCQA's Private Health Insurance Plan Rankings, 2011-15, HMO/POS/PPO.

    About Quest Diagnostics
    Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 43,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

    About Inovalon
    Inovalon is a leading technology company providing cloud-based platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and industry-leading subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon's unique achievement of value is delivered through the effective progression of "Turning Data into Insight, and Insight into Action®." Providing technology that supports nearly 500 healthcare organizations, Inovalon's platforms are informed by data pertaining to more than 837,000 physicians, 354,000 clinical facilities, and more than 139 million Americans. Data Diagnostics™ is the intellectual property of Inovalon. For more information, visit www.inovalon.com.

    Quest Diagnostics Contacts:
    Rachel Robbins, Greenough (Media): 617-275-6521, rrobbins@greenough.biz
    Wendy Bost, Quest Diagnostics (Media): 973-520-2800
    Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

    Inovalon Contacts:
    Kim E. Collins (Media): 301-809-4000 x 1473
    George Price (Investors): 301-809-4000 x 1190

    SOURCE Quest Diagnostics

  • CAMBRIDGE, MA, MADISON, NJ, and NEW YORK, NY - 18 Oct 2016: IBM Watson Health (NYSE: IBM) and Quest Diagnostics (NYSE: DGX) today announced the launch of IBM Watson Genomics from Quest Diagnostics, a new service that helps advance precision medicine by combining cognitive computing with genomic tumor sequencing. Memorial Sloan Kettering Cancer Center (MSK) will supplement Watson’s corpus of scientific data with OncoKB, a precision oncology knowledge base to help inform precision treatment options for cancer patients.

    The launch marks the first time that Watson for Genomics has been made widely available to patients and physicians across the country. Quest Diagnostics, a leader in genomic sequencing and oncology diagnostics that serves half the nation’s physicians and hospitals, extends these advanced capabilities to thousands  of the country’s community oncologists, who provide an estimated 70 percent of cancer care in the United States. The Broad Institute of MIT and Harvard will provide additional genome sequencing capabilities as part of the collaboration.

    The new service involves laboratory sequencing and analysis of a tumor’s genomic makeup to help reveal mutations that can be associated with targeted therapies and clinical trials. Watson then compares those mutations against relevant medical literature, clinical studies, pharmacopeia and carefully annotated rules created by leading oncologists, including those from MSK. Watson for Genomics ingests approximately 10,000 scientific articles and 100 new clinical trials every month.

    “The beauty of Watson is that it can be used to dramatically scale access to knowledge and scientific insight, whether a patient is being treated in an urban academic medical center or a rural community clinic,” said John Kelly III, PhD, senior vice president, IBM Research and Cognitive Solutions. “Through this collaboration with the cancer community’s leading clinical and pathology experts, thousands of more patients can potentially benefit from the world’s growing body of knowledge about this disease.”

    Bolstering the corpus of data Watson uses, MSK will provide OncoKB, a database of clinical evidence that will help Watson uncover treatment options that could target the specific genetic abnormalities that are causing the growth of the cancer. Comparison of literature that may take medical experts weeks to prepare can now be completed in significantly less time.

    “Precision medicine is changing the way we treat cancer and giving new hope to people living with the disease,” said Jay G. Wohlgemuth, M.D., chief medical officer and senior vice president of research, development and medical, Quest Diagnostics. “However, access to genomic sequencing and tumor analysis required to determine appropriate precision medicine treatments for a patient can be a challenge. This service combines Quest’s state-of-the-art tumor analysis and national access with the cognitive computing of IBM’s Watson and the deep cancer treatment expertise of MSK. This is a powerful combination that we believe it will leap frog conventional genomic services as a better approach for identifying targeted oncology treatments.”

    How the Solution Works

    The efficacy of cancer therapy often depends on the type of gene mutations occurring in the cancer tumor. Many of the latest therapies are designed to work by targeting tumors with a specific genetic makeup. A therapy that is effective for one type of cancer may in fact be efficacious for many others that share similar mutations. But these mutations vary for each individual and can even change during treatment. Correlating them to the appropriate treatments requires genomic sequencing expertise as well as information from knowledge bases, which must be routinely updated to account for rapidly evolving scientific discoveries, available drug therapies and, for patients for whom no therapy is indicated, and appropriate clinical trials.

    The new service helps close these gaps: To access Watson’s evidence-based report, the treating oncologist or other physician will send a patient’s solid tumor biopsy tissue to Quest Diagnostics, where pathologists will prepare the tissue sample for genomic sequencing. Scientists at Quest will then sequence the treatment-associated genes using advanced next-generation sequencing technologies and feed the genetic file into Watson. Watson will then use the sequenced genetic data and compare those data against massive bodies of clinical, scientific and pharmacological databases to help uncover potential therapeutic options that match the patient’s tumor mutations. A Quest pathologist will review and validate the results and prepare a report to send back to the treating physician.

     “We now know that genetic alterations are responsible for many cancers, but it remains challenging for most clinicians to deliver on the promise of precision medicine since it requires specialized expertise and a time-consuming interpretation of massive amounts of data,” said Paul Sabbatini, MD, Deputy Physician-in-Chief for Clinical Research, Memorial Sloan Kettering Cancer Center. “Through this collaboration, oncologists will have access to MSK’s expertly curated information about the effects and treatment implications of specific cancer gene alterations. This has the power to scale expertise and help improve patient care.”

    About IBM Watson Health

    Watson is the first commercially available cognitive computing capability representing a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions. In April 2015, the company launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated view of clinical, research and social health data. For more information on IBM Watson, visit: ibm.com/watson. For more information on IBM Watson Health, visit: ibm.com/watsonhealth.

    About Quest Diagnostics

    Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 44,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

    About Memorial Sloan Kettering

    Memorial Sloan Kettering is the world’s oldest and largest private cancer center, home to more than 14,000 physicians, scientists, nurses, and staff united by a relentless dedication to conquering cancer. As an independent institution, MSK combines 130 years of research and clinical leadership with the freedom to provide highly individualized, exceptional care to each patient. And MSK’s always-evolving educational programs continue to train new leaders in the field, here and around the world. For more information, go to www.mskcc.org.

    Contact(s) information

    Christine Douglass 
    IBM Media Relations 
    1 (415) 535-4479 
    cgdouglass@us.ibm.com

    Nicole McNamara 
    Memorial Sloan Kettering Media Relations 
    1 (646) 227-3633 
    mcnamarn@mskcc.org

    Kim Gorode 
    Quest Diagnostics Media Relations 
    1 (973) 520-2800 
    kimberly.b.gorode@questdiagnostics.com